Skip to main content
Dr. Lal Pathlabs Limited logo

Dr. Lal Pathlabs Limited — Investor Relations & Filings

Ticker · LALPATHLAB ISIN · INE600L01024 LEI · 984500E8E9CY102B9718 BSE.NS Human health and social work activities
Open in API
Filings indexed 1,098 across all filing types
Latest filing 2024-10-24 Regulatory Filings
Country IN India
Listing BSE.NS LALPATHLAB

About Dr. Lal Pathlabs Limited

https://www.lalpathlabs.com/

Dr. Lal Pathlabs Limited is a provider of diagnostic and related healthcare tests and services. The company offers a comprehensive range of clinical laboratory tests and profiles used for prediction, early detection, diagnostic screening, confirmation, and monitoring of diseases. Its service portfolio encompasses pathology, including biochemistry, hematology, clinical pathology, histopathology, and molecular diagnostics, as well as radiology services such as X-ray, ultrasound, and CT scans. The organization operates an extensive network of laboratories, patient service centers, and pick-up points, utilizing advanced automated systems and standardized processes. Key offerings include specialized wellness packages and home sample collection. The company maintains high quality standards through international and national accreditations, serving a diverse patient base and healthcare providers with a focus on accuracy and timely reporting.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (National Stock Exchange of India Limited and BSE Limited) regarding the publication of newspaper advertisements of the company's financial results for the quarter and half year ended September 30, 2024. It references compliance with SEBI regulations and mentions that the financial results were published in newspapers. The document itself is a notification or announcement about the publication of financial results advertisements, not the financial results report itself. The document length is 15,000 characters, but the content is primarily an announcement of the newspaper advertisement of financial results, not the detailed financial report or earnings release. Therefore, this fits best under Regulatory Filings (RNS) as a general regulatory announcement and notification rather than a direct financial report or earnings release.
2024-10-24 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a short announcement dated October 23, 2024, informing that the audio recording of the company's earnings conference call for Q2 & H1 FY25 is available on the company's website. It references the earnings call but does not contain the transcript or financial data itself. The document is under 5,000 characters and serves as a notification to the stock exchanges and public about the availability of the call recording. According to the rules, such announcements about the availability of conference call recordings or transcripts are classified as Call Transcript (CT) if the transcript is included, but here only the recording availability is mentioned. Since it is an announcement about the earnings call recording, not the transcript or the earnings release itself, the best fit is Call Transcript (CT) as it relates directly to the earnings call content. Confidence is high due to clear mention of earnings call and recording availability.
2024-10-23 English
Investor Presentation
Interim / Quarterly Report Classification · 95% confidence The document is titled as an "Earnings Presentation on Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2024." It contains detailed financial data for Q2 and H1 FY25, including revenue, EBITDA, PAT, EPS, and operational highlights. There is also management commentary and performance overview. The document is a presentation intended for analysts and investors, as indicated in the text. It is not a brief announcement or a certification letter, but a detailed presentation with substantive financial data and analysis for a period shorter than a full fiscal year (quarter and half year). Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q2 2025
2024-10-23 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated October 23, 2024, announcing the unaudited financial results for the quarter and half year ended September 30, 2024. It includes key financial highlights such as revenue, EBITDA, PAT, and dividend information. The document is titled as a press release and contains summary financial data but does not include comprehensive financial statements or detailed analysis typical of an Interim/Quarterly Report. The length is 4363 characters, which is relatively short and consistent with a press release rather than a full report. Therefore, this document fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly/periodical financial results with key highlights only. Q2 2025
2024-10-23 English
Cessation
Regulatory Filings
2024-10-23 English
Record Date
Regulatory Filings
2024-10-23 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.